Awakn Life Sciences Cash Flow Statement

Financials in millions CAD. Fiscal year is February - January.

Millions CAD. Fiscal year is Feb - Jan.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '24 Oct 31, 2024	Jan '24 Jan 31, 2024	Jan '23 Jan 31, 2023	Jan '22 Jan 31, 2022	Jan '21 Jan 31, 2021
Net Income	-2.22	-5.01	-9.14	-15.95	-1.26
Depreciation & Amortization	0.02	0.02	0.01	0.18	0.02
Stock-Based Compensation	0.19	0.81	0.63	1.09	0.05
Other Operating Activities	3.19	1.39	4.18	5.55	0.38
Change in Accounts Receivable	0.16	-0.01	-	-0	-
Change in Accounts Payable	0.33	0.9	0.43	1.02	0.3
Change in Unearned Revenue	0.1	0.01	-	0.01	-
Change in Other Net Operating Assets	0.2	0.28	0.05	-0.49	-0.13
Operating Cash Flow	2.25	-2.38	-7.36	-8.59	-0.63
Capital Expenditures	-	-	-	-1.7	-0.27
Cash Acquisitions	-	-	-	0.02	-0.02
Sale (Purchase) of Intangibles	-	-	-	-0.01	-
Other Investing Activities	0.06	-0.02	-0.1	-	-
Investing Cash Flow	-	-0.02	-0.1	-1.69	-0.29
Short-Term Debt Issued	-	-	-	3.86	-
Total Debt Issued	-	-	-	3.86	-
Long-Term Debt Repaid	-	-	-	-0.17	-
Total Debt Repaid	-	-	-	-0.17	-0.05
Net Debt Issued (Repaid)	-	-	-	3.68	-0.05
Issuance of Common Stock	1.15	2.66	5.97	7.49	1.46
Other Financing Activities	-	-0.2	0.43	0.33	-
Financing Cash Flow	1.15	2.46	6.4	11.5	1.41
Foreign Exchange Rate Adjustments	-0	-0.01	-0.02	0.03	-0
Net Cash Flow	3.4	0.04	-1.07	1.26	0.49
Free Cash Flow	2.25	-2.38	-7.36	-10.29	-0.9
Free Cash Flow Margin	3939.36%	-2725.57%	-	-4358.76%	-
Free Cash Flow Per Share	0.06	-0.08	-0.29	-0.47	-0.07
Levered Free Cash Flow	-0.8	-1.29	-2.02	-5.79	-
Unlevered Free Cash Flow	-0.8	-1.29	-2.02	-5.66	-
Change in Net Working Capital	-0.51	-0.33	-0.64	-0.89	-

Updated Dec 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.